Gm-Csf
Ovarian Cancer Stage 3
Georgetown UniversityPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Ovarian Cancer Stage 3 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ny-Eso-1 Peptide Vaccine Georgetown University | Phase 2 | B |
Toripalimab Georgetown University | Phase 2 | CCC |
Same molecule, other indications
Gm-Csf is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →